Nephros Competitors
| NEPH Stock | USD 4.25 0.06 1.39% |
Nephros vs Werewolf Therapeutics Correlation
Very weak diversification
The correlation between Nephros and HOWL is 0.52 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Nephros and HOWL in the same portfolio, assuming nothing else is changed.
Moving against Nephros Stock
| 0.51 | SHM | Shriro Holdings | PairCorr |
| 0.49 | HBB | Hamilton Beach Brands | PairCorr |
| 0.44 | SN | SharkNinja | PairCorr |
| 0.42 | FEBO | Fenbo Holdings | PairCorr |
| 0.41 | BRK-B | Berkshire Hathaway | PairCorr |
Nephros Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nephros and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Nephros and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nephros does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Nephros Stock performing well and Nephros Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nephros' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DXR | 2.53 | 0.08 | 0.01 | (0.17) | 3.95 | 4.22 | 21.64 | |||
| BEAT | 8.56 | 0.89 | 0.08 | 0.40 | 10.33 | 28.33 | 103.08 | |||
| ONMD | 7.15 | (1.30) | 0.00 | (0.43) | 0.00 | 13.71 | 53.01 | |||
| ICCC | 2.60 | (0.08) | (0.01) | 0.00 | 3.51 | 5.39 | 15.74 | |||
| OSTX | 3.12 | (0.54) | 0.00 | (0.33) | 0.00 | 5.49 | 16.39 | |||
| ZJYL | 4.74 | (0.97) | 0.00 | (0.83) | 0.00 | 8.00 | 46.56 | |||
| OTLK | 5.58 | (0.94) | 0.00 | 0.32 | 0.00 | 11.32 | 73.07 | |||
| NRXP | 4.00 | (0.53) | 0.00 | (0.63) | 0.00 | 7.34 | 21.29 | |||
| SPRB | 4.77 | (0.53) | 0.00 | (3.35) | 0.00 | 10.15 | 31.24 | |||
| HOWL | 4.70 | (1.19) | 0.00 | (0.62) | 0.00 | 7.69 | 51.90 |
Cross Equities Net Income Analysis
Compare Nephros and related stocks such as Daxor, Heartbeam, and OneMedNet Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXR | 1.8 M | (7.2 M) | 1.2 M | (8.2 M) | (976.7 K) | (9.1 M) | 1.5 M | (1.2 M) | (885.8 K) | (495.7 K) | (1.7 M) | 4.7 M | 5.2 M | 280.6 K | 536.3 K | 482.7 K | 649.4 K |
| BEAT | (12.7 M) | (61.4 M) | (12.2 M) | (7.3 M) | (9.8 M) | 7.4 M | 53.4 M | (16 M) | 42.8 M | (778 K) | (1.3 M) | (4.4 M) | (12.8 M) | (14.6 M) | (19.4 M) | (22.4 M) | (21.2 M) |
| ONMD | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.9 M) | (30.5 M) | (23.2 M) | (10.1 M) | (9.1 M) | (9.6 M) |
| ICCC | (1000 K) | (409.5 K) | 89.5 K | 117.4 K | (167.2 K) | 1.2 M | 508.4 K | (168 K) | (2.3 M) | (1.3 M) | (1 M) | (78.3 K) | (2.5 M) | (5.8 M) | (2.2 M) | (1.9 M) | (1.8 M) |
| OSTX | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (6 K) | (7.4 M) | (6.3 M) | (7.8 M) | (8.9 M) | (8 M) | (8.4 M) |
| ZJYL | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.6 M | 2.2 M | 2.6 M | 2.7 M | 2.9 M | 3.7 M | 3.7 M | 3.3 M | 2.4 M |
| OTLK | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (47.4 M) | (53.3 M) | (38.8 M) | (30.1 M) | (34.5 M) | (35.2 M) | (53.2 M) | (66.1 M) | (59 M) | (75.4 M) | (62.4 T) | (56.2 T) | (53.4 T) |
| NRXP | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | 66.1 K | 408.4 K | (51.8 M) | (93.1 M) | (39.8 M) | (30.1 M) | (25.1 M) | (22.6 M) | (23.7 M) |
| SPRB | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (13.2 M) | (29.5 M) | (42.3 M) | (46.2 M) | (47.9 M) | (53 M) | (47.7 M) | (50.1 M) |
| HOWL | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (14.9 M) | (49.8 M) | (51.6 M) | (37.4 M) | (70.5 M) | (63.5 M) | (60.3 M) |
Nephros and related stocks such as Daxor, Heartbeam, and OneMedNet Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Nephros financial statement analysis. It represents the amount of money remaining after all of Nephros operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Nephros Competitive Analysis
The better you understand Nephros competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nephros' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nephros' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Nephros Competition Performance Charts
Five steps to successful analysis of Nephros Competition
Nephros' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nephros in relation to its competition. Nephros' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Nephros in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nephros' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nephros, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Nephros position
In addition to having Nephros in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Nephros Correlation with its peers. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is there potential for Household Appliances market expansion? Will Nephros introduce new products? Factors like these will boost the valuation of Nephros. Anticipated expansion of Nephros directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.729 | Earnings Share 0.14 | Revenue Per Share | Quarterly Revenue Growth 0.354 | Return On Assets |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Nephros' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nephros should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Nephros' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.